GH

+ Watchlist + Portfolio

Guardant Health, Inc.

Regulated industry Sells to businessesTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $174.75
52-Week Range: $61.00 – $183.51
Market Cap: $23.86B
P/E (TTM): —
EPS (TTM): -3.50
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: —
Return on Assets: -18.07%
Gross Margin: 65.01%
Operating Margin: -38.25%
Profit Margin: -38.33%
Current Ratio: 4.03
Debt/Equity: —
Total Debt: $1.70B
Free Cash Flow: $26.61M
Revenue Growth: 44.30%
Earnings Growth: —
Enterprise Value: $24.50B

GH Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$449.54M	$563.95M	$739.02M	$982.02M
Cost of Revenue	$156.32M	$227.05M	$289.80M	$349.01M
Gross Profit	$293.21M	$336.90M	$449.22M	$633.01M
Research & Development	$373.81M	$367.19M	$347.75M	$364.19M
Selling, General & Admin	$463.78M	$451.03M	$545.06M	$706.07M
Operating Expenses	$837.59M	$901.62M	$892.81M	$1.07B
Operating Income	-$544.38M	-$564.73M	-$443.59M	-$437.25M
EBITDA	-$614.91M	-$433.31M	-$390.12M	-$373.91M
Pretax Income	-$653.45M	-$478.76M	-$435.09M	-$417.54M
Income Tax	$1.14M	$685.00K	$1.28M	-$1.26M
Net Income	-$654.59M	-$479.45M	-$436.37M	-$416.28M
Diluted EPS	-6.41	-4.28	-3.56	-3.32
Diluted Shares	102.18M	111.99M	122.75M	125.37M

GH Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$141.65M	$1.13B	$525.54M	$378.20M
Receivables	$97.26M	$88.78M	$110.25M	$137.85M
Inventory	$51.60M	$61.95M	$71.08M	$85.88M
Current Assets	$1.19B	$1.35B	$1.06B	$1.47B
Total Assets	$1.61B	$1.79B	$1.49B	$2.01B
Current Liabilities	$193.22M	$205.92M	$225.58M	$302.73M
Long-Term Debt	$1.14B	$1.14B	$1.14B	$1.50B
Total Debt	$1.37B	$1.35B	$1.34B	$1.71B
Total Liabilities	$1.55B	$1.63B	$1.63B	$2.11B
Retained Earnings	-$1.66B	-$2.14B	-$2.58B	-$2.99B
Shareholders' Equity	$60.18M	$158.68M	-$139.65M	-$99.31M
Working Capital	$998.37M	$1.14B	$829.53M	$1.16B
Net Debt	$995.74M	$6.43M	$617.01M	$1.13B

GH Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$309.46M	-$324.98M	-$239.86M	-$184.76M
Capital Expenditure	-$77.46M	-$20.49M	-$35.09M	-$48.31M
Free Cash Flow	-$386.92M	-$345.46M	-$274.94M	-$233.07M
Depreciation & Amortisation	$35.96M	$42.88M	$42.39M	$39.74M
Stock-Based Compensation	$94.69M	$90.76M	$140.41M	$166.22M
Investing Cash Flow	$149.82M	$840.25M	-$261.31M	-$627.20M
Financing Cash Flow	-$189.09M	$477.38M	-$996.00K	$671.13M
Share Repurchases	—	$0.00	$0.00	-$45.01M
Net Change in Cash	-$348.74M	$992.65M	-$502.16M	-$140.83M

GH Income statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$232.09M	$265.20M	$281.27M	$301.67M	$334.98M
Cost of Revenue	$81.20M	$93.59M	$99.49M	$104.92M	$115.95M
Gross Profit	$150.88M	$171.61M	$181.77M	$196.75M	$219.03M
Research & Development	$87.45M	$89.96M	$98.26M	$91.04M	$96.53M
Selling, General & Admin	$169.85M	$180.64M	$204.31M	$227.06M	$251.61M
Operating Expenses	$257.30M	$270.60M	$302.58M	$318.10M	$348.15M
Operating Income	-$106.41M	-$98.99M	-$120.81M	-$121.35M	-$129.12M
EBITDA	-$88.84M	-$82.24M	-$118.99M	-$100.91M	-$109.05M
Pretax Income	-$99.86M	-$92.59M	-$130.22M	-$111.70M	-$119.96M
Income Tax	$38.00K	$136.00K	-$1.73M	$372.00K	$185.00K
Net Income	-$99.90M	-$92.72M	-$128.49M	-$112.08M	-$120.14M
Diluted EPS	-0.80	-0.74	-1.00	-0.85	-0.90
Diluted Shares	124.11M	124.81M	128.66M	131.27M	132.87M

GH Balance Sheet statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$629.14M	$580.01M	$378.20M	$989.29M	$1.05B
Receivables	$130.25M	$115.58M	$137.85M	$137.40M	$144.25M
Inventory	$84.06M	$90.49M	$85.88M	$83.85M	$105.46M
Current Assets	$883.43M	$828.88M	$1.47B	$1.37B	$1.36B
Total Assets	$1.33B	$1.28B	$2.01B	$1.92B	$1.91B
Current Liabilities	$238.43M	$236.92M	$302.73M	$292.14M	$338.96M
Long-Term Debt	$1.12B	$1.11B	$1.50B	$1.50B	$1.50B
Total Debt	$1.33B	$1.33B	$1.71B	$1.70B	$1.70B
Total Liabilities	$1.64B	$1.63B	$2.11B	$2.10B	$2.14B
Retained Earnings	-$2.77B	-$2.87B	-$2.99B	-$3.11B	-$3.23B
Shareholders' Equity	-$305.48M	-$354.47M	-$99.31M	-$181.07M	-$222.87M
Working Capital	$645.00M	$591.97M	$1.16B	$1.08B	$1.03B
Net Debt	$486.38M	$534.58M	$1.13B	$514.18M	$449.47M

GH Cash Flow statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$60.28M	-$35.41M	-$26.37M	-$65.62M	-$57.78M
Capital Expenditure	-$5.65M	-$10.35M	-$27.85M	-$5.58M	-$11.76M
Free Cash Flow	-$65.93M	-$45.76M	-$54.22M	-$71.20M	-$69.54M
Depreciation & Amortisation	$10.04M	$9.41M	$10.05M	$9.44M	$9.56M
Stock-Based Compensation	$42.46M	$42.81M	$43.19M	$47.61M	$57.73M
Investing Cash Flow	-$10.65M	-$14.35M	-$905.07M	$699.42M	$101.47M
Financing Cash Flow	$1.62M	$4.33M	$732.03M	-$21.58M	$23.01M
Share Repurchases	$0.00	$0.00	$0.00	$0.00	$0.00
Net Change in Cash	-$69.31M	-$45.43M	-$199.41M	$612.22M	$66.71M

Market Snapshot

About

Guardant Health, Inc. is a precision oncology company focused on developing and commercializing blood-based liquid biopsy tests for cancer screening, diagnosis, and treatment monitoring. The company's flagship products include Guardant360, a comprehensive genomic profiling test for advanced cancer patients, and Guardant Reveal for minimal residual disease detection and recurrence monitoring. Guardant's Shield test is a blood-based screening solution for colorectal cancer in average-risk individuals. The company's liquid biopsy platform analyzes circulating tumor DNA (ctDNA) in blood samples, offering a less invasive alternative to traditional tissue biopsies. Guardant Health is at the forefront of precision medicine, partnering with pharmaceutical companies and healthcare providers to improve cancer outcomes.